Cargando…

The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats

Prevalent in approximately 20% of the worldwide human population, the rs6265 (also called ‘Val66Met’) single nucleotide polymorphism (SNP) in the gene for brain-derived neurotrophic factor (BDNF) is a common genetic variant that can alter therapeutic responses in individuals with Parkinson’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercado, Natosha M., Stancati, Jennifer A., Sortwell, Caryl E., Mueller, Rebecca L., Boezwinkle, Samuel A., Duffy, Megan F., Fischer, D. Luke, Sandoval, Ivette M., Manfredsson, Fredric P., Collier, Timothy J., Steece-Collier, Kathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855552/
https://www.ncbi.nlm.nih.gov/pubmed/33188920
http://dx.doi.org/10.1016/j.nbd.2020.105175
_version_ 1783646188629655552
author Mercado, Natosha M.
Stancati, Jennifer A.
Sortwell, Caryl E.
Mueller, Rebecca L.
Boezwinkle, Samuel A.
Duffy, Megan F.
Fischer, D. Luke
Sandoval, Ivette M.
Manfredsson, Fredric P.
Collier, Timothy J.
Steece-Collier, Kathy
author_facet Mercado, Natosha M.
Stancati, Jennifer A.
Sortwell, Caryl E.
Mueller, Rebecca L.
Boezwinkle, Samuel A.
Duffy, Megan F.
Fischer, D. Luke
Sandoval, Ivette M.
Manfredsson, Fredric P.
Collier, Timothy J.
Steece-Collier, Kathy
author_sort Mercado, Natosha M.
collection PubMed
description Prevalent in approximately 20% of the worldwide human population, the rs6265 (also called ‘Val66Met’) single nucleotide polymorphism (SNP) in the gene for brain-derived neurotrophic factor (BDNF) is a common genetic variant that can alter therapeutic responses in individuals with Parkinson’s disease (PD). Possession of the variant Met allele results in decreased activity-dependent release of BDNF. Given the resurgent worldwide interest in neural transplantation for PD and the biological relevance of BDNF, the current studies examined the effects of the rs6265 SNP on therapeutic efficacy and side-effect development following primary dopamine (DA) neuron transplantation. Considering the significant reduction in BDNF release associated with rs6265, we hypothesized that rs6265-mediated dysfunctional BDNF signaling contributes to the limited clinical benefit observed in a subpopulation of PD patients despite robust survival of grafted DA neurons, and further, that this mutation contributes to the development of aberrant graft-induced dyskinesias (GID). To this end, we generated a CRISPR knock-in rat model of the rs6265 BDNF SNP to examine for the first time the influence of a common genetic polymorphism on graft survival, functional efficacy, and side-effect liability, comparing these parameters between wild-type (Val/Val) rats and those homozygous for the variant Met allele (Met/Met). Counter to our hypothesis, the current research indicates that Met/Met rats show enhanced graft-associated therapeutic efficacy and a paradoxical enhancement of graft-derived neurite outgrowth compared to wild-type rats. However, consistent with our hypothesis, we demonstrate that the rs6265 genotype in the host rat is strongly linked to development of GID, and that this behavioral phenotype is significantly correlated with neurochemical signatures of atypical glutamatergic neurotransmission by grafted DA neurons.
format Online
Article
Text
id pubmed-7855552
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-78555522022-01-01 The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats Mercado, Natosha M. Stancati, Jennifer A. Sortwell, Caryl E. Mueller, Rebecca L. Boezwinkle, Samuel A. Duffy, Megan F. Fischer, D. Luke Sandoval, Ivette M. Manfredsson, Fredric P. Collier, Timothy J. Steece-Collier, Kathy Neurobiol Dis Article Prevalent in approximately 20% of the worldwide human population, the rs6265 (also called ‘Val66Met’) single nucleotide polymorphism (SNP) in the gene for brain-derived neurotrophic factor (BDNF) is a common genetic variant that can alter therapeutic responses in individuals with Parkinson’s disease (PD). Possession of the variant Met allele results in decreased activity-dependent release of BDNF. Given the resurgent worldwide interest in neural transplantation for PD and the biological relevance of BDNF, the current studies examined the effects of the rs6265 SNP on therapeutic efficacy and side-effect development following primary dopamine (DA) neuron transplantation. Considering the significant reduction in BDNF release associated with rs6265, we hypothesized that rs6265-mediated dysfunctional BDNF signaling contributes to the limited clinical benefit observed in a subpopulation of PD patients despite robust survival of grafted DA neurons, and further, that this mutation contributes to the development of aberrant graft-induced dyskinesias (GID). To this end, we generated a CRISPR knock-in rat model of the rs6265 BDNF SNP to examine for the first time the influence of a common genetic polymorphism on graft survival, functional efficacy, and side-effect liability, comparing these parameters between wild-type (Val/Val) rats and those homozygous for the variant Met allele (Met/Met). Counter to our hypothesis, the current research indicates that Met/Met rats show enhanced graft-associated therapeutic efficacy and a paradoxical enhancement of graft-derived neurite outgrowth compared to wild-type rats. However, consistent with our hypothesis, we demonstrate that the rs6265 genotype in the host rat is strongly linked to development of GID, and that this behavioral phenotype is significantly correlated with neurochemical signatures of atypical glutamatergic neurotransmission by grafted DA neurons. 2020-11-11 2021-01 /pmc/articles/PMC7855552/ /pubmed/33188920 http://dx.doi.org/10.1016/j.nbd.2020.105175 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Mercado, Natosha M.
Stancati, Jennifer A.
Sortwell, Caryl E.
Mueller, Rebecca L.
Boezwinkle, Samuel A.
Duffy, Megan F.
Fischer, D. Luke
Sandoval, Ivette M.
Manfredsson, Fredric P.
Collier, Timothy J.
Steece-Collier, Kathy
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title_full The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title_fullStr The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title_full_unstemmed The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title_short The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
title_sort bdnf val66met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855552/
https://www.ncbi.nlm.nih.gov/pubmed/33188920
http://dx.doi.org/10.1016/j.nbd.2020.105175
work_keys_str_mv AT mercadonatosham thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT stancatijennifera thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT sortwellcaryle thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT muellerrebeccal thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT boezwinklesamuela thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT duffymeganf thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT fischerdluke thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT sandovalivettem thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT manfredssonfredricp thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT colliertimothyj thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT steececollierkathy thebdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT mercadonatosham bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT stancatijennifera bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT sortwellcaryle bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT muellerrebeccal bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT boezwinklesamuela bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT duffymeganf bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT fischerdluke bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT sandovalivettem bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT manfredssonfredricp bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT colliertimothyj bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats
AT steececollierkathy bdnfval66metpolymorphismrs6265enhancesdopamineneurongraftefficacyandsideeffectliabilityinrs6265knockinrats